Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 12 January 2026 - 13 January 2026

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

New York, January 12, 2026, 20:17 (EST) — Market closed. Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at…
13 January 2026
···
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors digested the company’s new five-year strategy and 2026 revenue outlook, rolled out around the J.P. Morgan Healthcare Conference in San…
13 January 2026
····
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

New York, Jan 12, 2026, 19:48 EST — After-hours AbbVie shares barely moved in after-hours Monday following a new three-year pricing pact with the Trump administration. The drugmaker also announced two deals to strengthen its pipeline and boost U.S. manufacturing. The stock slipped less than 0.1% to $220.04. The timing is crucial as Washington ramps up pressure on drugmakers over…
13 January 2026
····
Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

New York, January 12, 2026, 5:46 PM EST — After-hours Eli Lilly stock rose about 1.6% in after-hours trading on Monday, last at $1,081, after a top research executive said the drugmaker expects to have enough supply to launch its experimental weight-loss pill orforglipron in “many, many countries” as it nears a U.S. regulatory decision. (Reuters) The comments matter now…
13 January 2026
···
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and…
12 January 2026
····
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The…
12 January 2026
····
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

New York, January 12, 2026, 14:42 EST — Regular session. Merck & Co shares slipped $1.26, or 1.1%, to $109.27 in Monday afternoon trading. The stock has fluctuated between $111.45 and $108.95 today. Investors want clarity on Merck’s next steps beyond Keytruda and its legacy blockbusters. The upcoming J.P. Morgan Healthcare Conference promises to bring that question into sharp focus.…
12 January 2026
····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

New York, Jan 12, 2026, 2:38 PM EST — Regular session Shares of Johnson & Johnson climbed roughly 2.3% to $209.03 on Monday, pushing the stock near the high end of its trading range after new oncology data came out over the weekend. This move is crucial as major drugmakers face mounting pressure to demonstrate lasting growth ahead of earnings…
12 January 2026
····
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how…
12 January 2026
···
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

New York, Jan 12, 2026, 11:53 EST — Regular session Shares of Recursion Pharmaceuticals climbed Monday following the release of an updated investor presentation via a Form 8-K filing. The Nasdaq-traded stock gained 4.4%, reaching $4.87 late morning, putting the company’s market cap near $2.1 billion. (SEC) The filing comes as executives and investors gather in San Francisco for the…
12 January 2026
····
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

New York, Jan 12, 2026, 11:17 EST — Regular session Shares of Revolution Medicines (RVMD) slipped around 1.8% to $116.51 in early Monday trading, pulling back from a 52-week peak amid fresh analyst notes following a rollercoaster week of takeover rumors. The stock fluctuated between $113.47 and $119.58 during the session, pegging the company’s market cap at about $23 billion.…
12 January 2026
···
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

New York, Jan 12, 2026, 10:58 EST — Regular session Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery. The news comes as executives and investors gather at the J.P. Morgan Healthcare Conference in…
12 January 2026
····
1 … 5 6 7 8 9 … 45

Stock Market Today

  • GameStop Shares Rise After CEO Ryan Cohen Buys Additional Stock
    January 22, 2026, 8:23 AM EST. GameStop (NYSE:GME) shares rose about 3.5% pre-market following CEO Ryan Cohen's purchase of 500,000 shares at an average $21.12 each, totaling approximately $10.6 million. Cohen's ownership now reaches 9.2%, with over 41.5 million shares including warrants. Cohen, a key figure in GameStop's turnaround, became CEO in September 2023, serving without salary. The recent buy comes amid investor scrutiny of the company's ongoing profitability improvements, despite the stock declining over 20% in the past year. Earlier this month, Cohen received performance-based stock options tied to long-term targets.
Go toTop